When was Meiogenix founded?

Meiogenix was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Meiogenix located?

Meiogenix is headquartered in Paris, France.

Who is the current CEO of Meiogenix?

Giacomo Bastianelli and Luc Mathis s of Meiogenix. Giacomo Bastianelli has also founded 1 company.

How many employees does Meiogenix have?

As of Feb 17, 2026, the latest employee count at Meiogenix is 19.

Is Meiogenix a funded company?

Meiogenix is a funded company, having raised a total of $13M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 26, 2010.

When was the latest funding round of Meiogenix?

Meiogenix's latest funding was a $***** Series A round on Dec 14, 2021, with participation from 5 investors. Its primary sector is Life Sciences Platforms and Tools. Globally, the Life Sciences Platforms and Tools sector has seen $600M in funding in 2026 to date.

Where does Meiogenix rank among its competitors?

Meiogenix ranks 92nd amongst 2219 active competitors, of which 529 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Meiogenix?

Meiogenix's top competitors include Synthego, Advanta and Cibus. Among them, Antheia secured the most recent funding round in January, 2026.

Meiogenix - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of novel breeding technologies for crop plants. The platform uses a fusion protein which is designed to increase the recombination rates in cold regions. It has created disruptive solutions that can significantly impact agricultural practices and improve crop resilience, quality, and yield.

Website: meiogenix.com
Email ID: *****@meiogenix.com

Key Metrics

Founded Year

2010

Location

Paris, France

Stage

Series A

Total Funding

$13M in 3 rounds

Latest Funding Round

Series A, Dec 14, 2021, $*****

Investors

Sofinnova Partners & 5 more

Ranked

92^nd among 2219 active competitors

Employee Count

19 as on Feb 17, 2026

Similar Companies

Synthego & 2967 more

View Meiogenix's full profile

Meiogenix has raised a total funding of $13M over 3 rounds. Its first funding round was on Nov 26, 2010. Its latest funding round was a Series A round on Dec 14, 2021 for $*****. 5 investors participated in its latest round. Meiogenix has 6 institutional investors.

Here is the list of recent funding rounds of Meiogenix:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 14, 2021	9033083	Series A	9265172	6374284	2625875	9690398
Apr 26, 2016	5670663	Grant (prize money)	9574684	4903518	2342693	6797065
Nov 26, 2010	8002450	Series A	6904774	2821191	5889914	Kurma Partners

Access funding benchmarks and valuations. Sign up today!

View details of Meiogenix's funding rounds and investors

The founders of Meiogenix is Giacomo Bastianelli. Luc Mathis is the CEO of Meiogenix.

Here are the details of Meiogenix's key team members:

Giacomo Bastianelli: Former Co-Founder & CEO of Meiogenix and founder of 2 other companies, Key Neurosciences and SCI-BRAIN.
Luc Mathis: Former Founder & CEO of Meiogenix.
Contact Info: 1 email address

View details of Meiogenix's Founder profiles and Board Members

Meiogenix's employee count trend

Meiogenix has 19 employees as of Feb 26. Here is Meiogenix's employee count trend over the years:

Uncover Meiogenix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Meiogenix include Synthego, Advanta and Cibus. Here is the list of Top 10 competitors of Meiogenix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Advanta 1989, Dubai (United Arab Emirates), Public	Developer of high-nutrition crops for sustainable agriculture	$400M	KKR, Alpha Wave Global & 5 others	70/100
3rd	Cibus 2001, San Diego (United States), Public	Developer of precision breeding technologies for resilient and vigorous crops	$34.5M	Fidelity Investments, Qubis & 7 others	69/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	69/100
5th	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	68/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Citadel, Point72 & 14 others	67/100
7th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Logos & 19 others	67/100
8th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
9th	Tropic Biosciences 2016, Norwich (United Kingdom), Series C	Developer of gene editing technologies for improved tropical crop production	$73.5M	Temasek, Aliment Capital & 32 others	66/100
10th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, China Structural Reform Fund ... & 11 others	66/100
92nd	Meiogenix 2010, Paris (France), Series A	Developer of novel breeding technologies for crop plants	$13M	Alexandria, Casdin Capital & 4 others	53/100